Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23121049 | 0.91 | GPR119 (0.46) | GPR119HRH3CHEK2KDM1ADDB1 | |
| SCHEMBL31040953 | 0.89 | KDM1A (0.52) | GPR119HRH3CHEK2KDM1ADDB1 | |
| SCHEMBL31040946 | 0.85 | GPR119 (0.48) | GPR119HRH3CHEK2KDM1ADDB1 | |
| SCHEMBL31040957 | 0.85 | GPR119 (0.48) | GPR119HRH3CHEK2KDM1ADDB1 | |
| SCHEMBL22119552 | 0.85 | DDB1 (0.57) | GPR119HRH3DDB1CRBN | |
| SCHEMBL23121408 | 0.85 | GPR119 (0.48) | GPR119DDB1CRBN | |
| SCHEMBL23120916 | 0.84 | DDB1 (0.52) | HRH3DDB1CRBN | |
| SCHEMBL24480492 | 0.84 | GPR119 (0.66) | GPR119DDB1CRBN | |
| SCHEMBL23410203 | 0.83 | GPR119 (0.56) | GPR119HRH3CHEK2KDM1ANPBWR1 | |
| SCHEMBL22119507 | 0.82 | DDB1 (0.59) | GPR119DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | GPR119 3689/4885HRH3 4251/4885CHEK2 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.